Dr. Seymour on the Efficacy Ibrutinib Versus Chemoimmunotherapy in Older Patients With CLL

Video

Erlene Seymour, MD, discusses the use of ibrutinib versus chemoimmunotherapy in older patients with untreated chronic lymphocytic leukemia.

Erlene Seymour, MD, an assistant clinical professor at Wayne State University School of Medicine and a hematologist/oncologist at Barbara Ann Karmanos Cancer Institute, discusses the use of ibrutinib (Imbruvica) versus chemoimmunotherapy in older patients with untreated chronic lymphocytic leukemia (CLL).

Data from a randomized phase 3 trial (NCT01886872) revealed that treatment with ibrutinib led to improved progression-free survival (PFS) versus treatment with bendamustine and rituximab (Rituxan; BR) in older patients with previously untreated CLL.

Additional analyses showed that patients with IGHV-mutated CLL experienced longer PFS versus patients with IGHV-unmutated disease.

The observed safety profile of ibrutinib was as expected and included atrial fibrillation, bleeding, and diarrhea. However, higher rates of hypertension were observed compared with clinical experience, concludes Seymour.

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center